A new combination therapy appears to boost the response rate for liver cancer patients receiving immunotherapy, accordin ...
Inhibiting a certain protein in mice reduced obesity-induced liver tumor development, Yale researchers found. It could reveal ...
A predictive model using plasma proteins as biomarkers predicted hepatocellular carcinoma development more accurately than a ...
Among more than 1,300 patients diagnosed with HCC, the median survival reached 37 months for those with screening-detected ...
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to ...
Michael Morse, MD, FACP, MHS, medical oncologist at Duke Cancer Center, explained the importance of managing toxicities in ...
According to a study published in the journal Nature Medicine, people with Hepatocellular Carcinoma treated with ...
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety.
Early detection has the potential to transform treatment and outcomes in cancer care, especially for cancers like liver cancer, which is typically diagnosed at a late stage with limited options for ...
In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first ...
As a malignant disease of the liver cells, hepatocellular carcinoma (HCC) is one of the main causes of cancer-related deaths. While the treatment options for this aggressive type of cancer remain ...
Early detection has the potential to transform treatment and outcomes in cancer care, especially for cancers like liver cancer, which is typically diagnosed at a late stage with limited options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback